Episode Details
Back to Episodes317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
Published 2 years, 2 months ago
Description
STAT's Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI drug development companies Recursion Pharmaceuticals and Exscientia, Novo Nordisk's decision to pause its regulatory submission for Wegovy's use in patients with heart failure with preserved ejection fraction, and the state of biotech VC.